{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:03:30Z","timestamp":1785553410035,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K23-HL148539"],"award-info":[{"award-number":["K23-HL148539"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.kint.2022.04.023","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T20:38:49Z","timestamp":1653338329000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-4814","authenticated-orcid":false,"given":"Joyce C.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela F.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Wenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.04.023_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/acr.21558","article-title":"Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus","volume":"64","author":"Mina","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2022.04.023_bib2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2022.04.023_bib3","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2022.04.023_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2013.07.007","article-title":"Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal","volume":"43","author":"Tselios","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.kint.2022.04.023_bib5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.21998","article-title":"International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus: obtainment of international consensus for childhood-onset SLE","volume":"65","author":"Hollander","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2022.04.023_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.04.023_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.04.023_bib8","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.04.023_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1191\/0961203305lu2076oa","article-title":"Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy","volume":"14","author":"Kanda","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2022.04.023_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1191\/0961203305lu2249oa","article-title":"Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria","volume":"14","author":"Tse","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2022.04.023_bib11","first-page":"892","article-title":"Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis","volume":"37","author":"Kitamura","year":"2009","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.kint.2022.04.023_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","article-title":"When should we start and stop ACEi\/ARB in paediatric chronic kidney disease?","volume":"36","author":"Chan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2022.04.023_bib14","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/0961203314543917","article-title":"Identification of patients with systemic lupus erythematosus in administrative healthcare databases","volume":"23","author":"Hanly","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2022.04.023_bib15","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/art.34472","article-title":"Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population","volume":"64","author":"Hiraki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2022.04.023_bib16","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/acr.23485","article-title":"High health care utilization preceding diagnosis of systemic lupus erythematosus in youth","volume":"70","author":"Chang","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.kint.2022.04.023_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/0961203309356289","article-title":"Identification and validation of lupus nephritis cases using administrative data","volume":"19","author":"Chibnik","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2022.04.023_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2215\/CJN.07810621","article-title":"Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes","volume":"17","author":"Wenderfer","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.04.023_bib19","first-page":"449","article-title":"Estimating medication persistency using administrative claims data","volume":"11","author":"Sikka","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.kint.2022.04.023_bib20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/j.1475-6773.2009.00989.x","article-title":"New prescription medication gaps: a comprehensive measure of adherence to new prescriptions","volume":"44","author":"Karter","year":"2009","journal-title":"Health Services Res"},{"key":"10.1016\/j.kint.2022.04.023_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.kint.2022.04.023_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.04.023_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.kint.2022.04.023_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.kint.2022.04.023_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.kint.2022.04.023_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.kint.2022.04.023_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.kint.2022.04.023_bib28","doi-asserted-by":"crossref","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","article-title":"Weight trimming and propensity score weighting","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2022.04.023_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.04.023_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.04.023_bib31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00467-006-0060-3","article-title":"Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children","volume":"21","author":"Lau","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2022.04.023_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2022.04.023_bib33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"10.1016\/j.kint.2022.04.023_bib34","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.04.023_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2022.04.023_bib36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.prostaglandins.2005.08.001","article-title":"Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients","volume":"78","author":"Daza","year":"2005","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.kint.2022.04.023_bib37","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial: early response to treatment predicts good outcome in lupus nephritis","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2022.04.023_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.04.023_bib39","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2022.04.023_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2249.2000.01323.x","article-title":"Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals: captopril inhibits apoptosis in T cells","volume":"121","author":"Odaka","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2022.04.023_bib41","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2022.04.023_bib42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/art.22674","article-title":"Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus","volume":"57","author":"Yazdany","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2022.04.023_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/acr.23285","article-title":"Delays to care in pediatric lupus patients: data from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"70","author":"Rubinstein","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2022.04.023_bib44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/acr2.11314","article-title":"Factors associated with variation in pediatric systemic lupus erythematosus care delivery","volume":"3","author":"Burnham","year":"2021","journal-title":"ACR Open Rheuma"},{"key":"10.1016\/j.kint.2022.04.023_bib45","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1177\/0961203318809883","article-title":"Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression","volume":"27","author":"Castro","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2022.04.023_bib46","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/acr.24392","article-title":"Immunomodulatory medication use in newly diagnosed youth with systemic lupus erythematosus","volume":"73","author":"Davis","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2022.04.023_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pds.4649","article-title":"Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data","volume":"28","author":"Joseph","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822003738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822003738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:14:21Z","timestamp":1785550461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822003738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0085253822003738"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.04.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}